Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.

@article{Valentino2010AssessingTB,
  title={Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.},
  author={L A Valentino},
  journal={Haemophilia : the official journal of the World Federation of Hemophilia},
  year={2010},
  volume={16 2},
  pages={263-71}
}
SUMMARY Prophylaxis with concentrates of factor VIII has become the standard of care for patients with severe haemophilia A because of its ability to prevent joint and other bleeding events. Recent evidence suggests that the prophylactic use of bypassing therapy--activated prothrombin complex concentrate (aPCC) and recombinant activated factor VII (rFVIIa)--provides similar benefits to haemophilia patients with inhibitors. To assess the efficacy and safety of prophylaxis with the aPCC FEIBA, a… CONTINUE READING